

Albert J Chang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4749311/publications.pdf>

Version: 2024-02-01

33
papers

692
citations

840776

11
h-index

552781

26
g-index

33
all docs

33
docs citations

33
times ranked

1309
citing authors

#	ARTICLE	IF	CITATIONS
1	High-risk prostate cancerâ€™ classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 308-323.	27.6	340
2	The American Brachytherapy Society consensus statement on intraoperative radiation therapy. <i>Brachytherapy</i> , 2019, 18, 242-257.	0.5	53
3	Patterns of Local Failure following Radiation Therapy for Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 977-982.	0.4	39
4	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020, 77, 201-208.	1.9	37
5	Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 178-187.	1.9	22
6	Improved rectal dosimetry with the use of SpaceOAR during high-dose-rate brachytherapy. <i>Brachytherapy</i> , 2018, 17, 259-264.	0.5	22
7	Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plans in Patients With Prostate Cancer. <i>Urology</i> , 2019, 125, 154-162.	1.0	20
8	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. <i>Radiotherapy and Oncology</i> , 2020, 151, 26-32.	0.6	19
9	Socioeconomic and Racial Determinants of Brachytherapy Utilization for Cervical Cancer: Concerns for Widening Disparities. <i>JCO Oncology Practice</i> , 2021, 17, e1958-e1967.	2.9	19
10	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	7.1	18
11	18F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate- to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons. <i>Radiology</i> , 2017, 282, 429-436.	7.3	15
12	Society of Interventional Radiology Multidisciplinary Position Statement on Percutaneous Ablation of Non-small Cell Lung Cancer and Metastatic Disease to the Lungs. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1241.e1-1241.e12.	0.5	15
13	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	5.9	12
14	Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience. <i>Brachytherapy</i> , 2019, 18, 470-476.	0.5	10
15	Respiration-Induced Intraorgan Deformation of the Liver: Implications for Treatment Planning in Patients Treated With Fiducial Tracking. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 776-782.	1.9	9
16	Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. <i>JAMA Network Open</i> , 2020, 3, e2017144.	5.9	6
17	Payment Methodology for the Radiation Oncology Alternative Payment Model: Implications for Practices and Suggestions for Improvement. <i>JCO Oncology Practice</i> , 2021, 17, 761-764.	2.9	5
18	Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation. <i>Radiation Oncology</i> , 2021, 16, 99.	2.7	4

#	ARTICLE	IF	CITATIONS
19	High-Dose Rate Interstitial Spine Brachytherapy Using an Intraoperative Mobile Computed Tomography-Guided Surgical Navigation System. <i>Operative Neurosurgery</i> , 2021, 21, 507-515.	0.8	4
20	Prostate-Specific Membrane Antigen Positron Emission Tomographyâ€“Identified Para-aortic Prostate Cancer Recurrence After Surgery and Salvage Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 261-262.	0.8	3
21	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 327-330.	5.4	3
22	American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. <i>Brachytherapy</i> , 2022, 21, 63-74.	0.5	3
23	Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel. <i>Frontiers in Oncology</i> , 2022, 12, 853246.	2.8	3
24	The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines. <i>Journal of Clinical Oncology</i> , 2018, 36, 3342-3344.	1.6	2
25	Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost. <i>Radiation Oncology</i> , 2022, 17, 12.	2.7	2
26	Safety lead-in of phase II SBRT and durvalumab with or without tremelimumab for unresectable and cisplatin-ineligible, locally advanced or metastatic bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 517-517.	1.6	2
27	Cautious Optimism for Extreme Dose Escalation in Prostate Cancer. <i>European Urology</i> , 2013, 64, 939-940.	1.9	1
28	Use of stereotactic body radiotherapy in gynecologic cancers: Local control with systemic treatment implications. <i>Gynecologic Oncology</i> , 2020, 159, 599-600.	1.4	1
29	Clinical Development and Evaluation of Megavoltage Topogram for Fast Patient Alignment on Helical Tomotherapy. <i>Advances in Radiation Oncology</i> , 2020, 5, 1334-1341.	1.2	1
30	Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e94-e103.	1.9	1
31	M2 macrophage increase in prostate adenocarcinoma after high-dose rate brachytherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 271-271.	1.6	1
32	Editorial Comment. <i>Urology</i> , 2014, 84, 1387-1388.	1.0	0
33	In Reply to Gensheimer and Trister. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1594-1596.	0.8	0